Frequency and Clinical Manifestations of Human Herpesvirus-6 Infection in Hematopoietic Stem Cell Transplant Recipients.
- Author:
Jung Hyun CHOI
1
;
Dong Gun LEE
;
Wan Shik SHIN
;
Jin Han KANG
;
Tai Gyu KIM
;
Soon Young PAIK
;
Hoon HAN
;
Chang Ki MIN
;
Dong Wook KIM
;
Jong Wook LEE
;
Woo Sung MIN
;
Chun Choo KIM
Author Information
1. Catholic Hematopoietic Stem Cell Transplantation Center, Catholic University of Korea, Seoul, Korea.
- Publication Type:Original Article
- Keywords:
Human herpesvirus-6;
Hematopoietic stem cell transplantation
- MeSH:
Cytomegalovirus Infections;
DNA;
Fever;
Graft vs Host Disease;
Hematopoietic Stem Cell Transplantation;
Hematopoietic Stem Cells*;
Herpesvirus 6, Human;
Humans*;
Korea;
Polymerase Chain Reaction;
Prevalence;
Prospective Studies;
Transplantation*
- From:Korean Journal of Infectious Diseases
2000;32(4):280-286
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND: Human herpesvirus-6 (HHV-6) is recently known as a major pathogen associated with various diseases in hematopoietic stem cell transplant (HSCT) recipients. We prospectively evaluated the frequency and clinical manifestations of HHV-6 infection in HSCT recipient in a single HSCT center in Korea. METHODS: Serum and peripheral blood mononuclear cells (PBMC) were weekly obtained from 1 week before HSCT to 4 weeks after HSCT. Three months' and six months' samples were obtained in some cases. HHV-6 was detected by nested polymerase chain reaction. RESULTS: Two hundred and seventy-eight samples from 54 HSCT recipients were collected from February to November, 1999. HHV-6 was detected in 32 out of 54 recipients (59.3%) at least once during study period in their PBMC or serum. HHV-6 DNA positive rate of PBMC and serum samples were 38.1% and 4.3 % respectively. HHV-6 DNAemia (HHV-6 DNA positive in serum) was detected and peaked at 2 weeks after HSCT and continued to 4 weeks. HHV-6 DNA in peripheral blood was not associated with unexplained fever, acute graft-versus-host disease, engraftment delay, or cytomegalovirus infection in this study. CONCLUSION: Reactivation and development of DNAemia of HHV-6 certainly occurred after HSCT, but the clinical manifestations and association with other diseases were unclear in this study. The large-scaled, nation-wide detail studies about the prevalence and characteristics of HHV-6 in general population and patients of specific disease entities must be considered.